Managing metastatic hormone-sensitive prostate cancer requires rapid risk stratification and intensified treatment. While clinical trials established local prostate radiation for low-volume disease, the clinical value of radiotherapy in high-volume mHSPC remains controversial. Recent retrospective research published in The Prostate offers fresh clinical insights. The investigation evaluated whether adding prostate-directed radiotherapy improves progression outcomes in patients receiving upfront doublet therapy. Furthermore, investigators analyzed the synergistic impact of metastasis-directed radiotherapy in this setting.

Evolving Standards and Radiotherapy in High-Volume mHSPC

Historically, clinicians reserved local prostate radiation primarily for oligometastatic or low-volume disease. Landmark clinical trials demonstrated clear overall survival advantages in low-volume cohorts. Conversely, standard guidelines traditionally excluded patients with high-volume burden from receiving routine local radiation. High-volume disease involves visceral metastases or four or more bone lesions, with at least one beyond the pelvis or vertebral column. Consequently, systemic doublet or triplet therapy remains the cornerstone of management for these individuals.

However, emerging biological evidence suggests that primary prostate tumors continuously shed circulating tumor cells. These primary lesions produce systemic paracrine signals that foster distant metastatic niches. Therefore, eliminating the primary prostatic focus could delay systemic treatment resistance. Modern upfront doublet regimens combine androgen deprivation therapy with potent androgen receptor pathway inhibitors. When clinicians combine these effective systemic drugs with targeted local therapy, patient outcomes might improve significantly. Thus, researchers designed this study to evaluate whether primary cytoreduction enhances systemic therapeutic durability.

Key Findings on Castration Resistance-Free Survival

The retrospective multicenter cohort study evaluated 239 patients diagnosed with synchronous high-volume disease between 2018 and 2025. All participants received upfront doublet therapy as initial systemic management. The investigators divided patients into a prostate-directed radiotherapy cohort and a non-radiotherapy control group. The primary study endpoint was castration resistance-free survival.

Because patients initiated local radiotherapy at a median of 7.0 months, researchers conducted a 7-month landmark analysis. This method effectively eliminated immortal time bias between cohorts. Additionally, researchers excluded patients who experienced disease progression before the landmark cutoff. In the propensity score-matched cohort, prostate-directed radiotherapy yielded a remarkable survival benefit. Specifically, the hazard ratio for progression to castration resistance was 0.47, reaching statistical significance. Furthermore, time-dependent multivariable Cox regression confirmed this independent protective association. Consequently, patients receiving local radiation experienced delayed disease progression compared to systemic therapy alone.

Investigating the Synergy of Metastasis-Directed Radiotherapy

Beyond primary prostate radiation, the study explored metastasis-directed radiotherapy as an adjunct intervention. In advanced clinical practice, radiation oncologists increasingly employ stereotactic body radiation to ablate oligoprogressive or dominant metastatic sites. Interestingly, the interaction analysis demonstrated that the survival benefit of metastasis-directed therapy varied according to primary radiation status.

Specifically, combining prostate-directed radiation with metastasis-directed therapy achieved an impressive hazard ratio of 0.37 for progression risk. This significant interaction highlights potential biological synergy between comprehensive primary cytoreduction and metastatic ablation. When clinicians sterilize both primary and secondary clones, they reduce overall tumor burden substantially. Furthermore, this dual approach may reduce polyclonal seeding across multiple metastatic compartments. Therefore, targeted radiation could prevent dominant metastatic foci from developing early endocrine resistance. While these exploratory interaction results remain hypothesis-generating, they provide compelling rationale for comprehensive radiation strategies in selected patients.

Clinical Implications for Multidisciplinary Oncology Teams

These retrospective findings offer practical considerations for clinicians managing advanced prostate cancer. In contemporary practice, oncologists frequently use advanced PSMA PET imaging at baseline diagnosis. Consequently, staging precision has increased, revealing the exact anatomical extent of metastatic lesions. When patients achieve substantial biochemical responses after six months of doublet therapy, consolidating local disease becomes an attractive option.

However, clinicians must carefully weigh potential toxicities against prospective clinical benefits. Prostate radiation can cause acute or late genitourinary and gastrointestinal side effects. Similarly, delivering radiation to multiple metastatic bone sites requires precise dosimetry and careful target contouring. Furthermore, upfront systemic intensification with doublet or triplet regimens remains the foundational standard of care. Radiation should never replace optimal systemic therapy. Instead, multidisciplinary teams should evaluate whether consolidating responsive disease improves disease control for selected individuals.

Future Research Directions and Trial Validation

Despite encouraging results, oncologists must interpret retrospective findings with appropriate scientific caution. The study cohort included a relatively modest number of irradiated patients, which introduces potential selection bias. Furthermore, retrospective designs cannot eliminate all unmeasured confounding variables despite rigorous propensity score matching. Prospective randomized clinical trials are essential to validate whether local radiation extends overall survival in high-volume cohorts.

Fortunately, ongoing prospective trials continue to evaluate comprehensive local and metastatic consolidation strategies. Researchers are investigating how modern radiopharmaceuticals, stereotactic ablative radiotherapy, and triplet systemic therapies interact. Additionally, molecular biomarkers and circulating tumor DNA may soon help identify patients who benefit most from radical local treatment. Meanwhile, clinicians should engage in transparent shared decision-making with patients regarding experimental radiation approaches. Ultimately, optimizing systemic therapy alongside judicious local consolidation may redefine future standards of care.

What is the primary objective of prostate-directed radiotherapy in high-volume mHSPC?

Prostate-directed radiotherapy aims to ablate the primary tumor and disrupt systemic tumor seeding in metastatic disease. Although traditional guidelines reserve prostate radiation for low-volume disease, recent findings indicate that local cytoreduction may delay castration resistance in high-volume cohorts. By eradicating aggressive primary clones, radiotherapy enhances the durability of upfront systemic doublet therapy. Consequently, this intervention may extend castration resistance-free survival and reduce painful local genitourinary complications over time.

How does metastasis-directed radiotherapy complement primary prostate radiation?

Metastasis-directed radiotherapy targets and destroys active secondary metastatic lesions using stereotactic body radiation. When clinicians combine primary prostate radiation with metastatic ablation, they eradicate resistant clones across multiple anatomical sites simultaneously. This comprehensive cytoreductive strategy reduces overall tumor burden and prevents cross-seeding between distant metastases. Consequently, recent interaction analyses demonstrate a significant synergistic reduction in progression risk when both primary and metastatic radiation treatments are delivered alongside systemic therapy.

Should clinicians routinely offer radiotherapy to all patients with high-volume disease?

Clinicians should not offer routine local radiotherapy to all high-volume patients outside prospective clinical trials. Current standard guidelines mandate intensified systemic doublet or triplet therapy as foundational management. While retrospective evidence shows promising delays in castration resistance, definitive overall survival validation remains necessary through prospective randomized trials. Therefore, multidisciplinary teams should evaluate radiotherapy on a case-by-case basis, considering individual treatment response, performance status, symptom burden, and patient preferences after adequate counseling.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Healthcare professionals should make clinical decisions based on individual patient assessments and refer to the latest local and national guidelines for clinical practice.

References

1. Koguchi D et al. Prognostic Impact of the Addition of Prostate-Directed Radiotherapy With or Without Metastasis-Directed Radiotherapy Under Upfront Doublet Therapy for High-Volume Metastatic Hormone-Sensitive Prostate Cancer. Prostate. 2026 Aug 23. doi: 10.1002/pros.70238. PMID: 42633691.
2. Burdett S, Boeve LM, Ingleby FC, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019;76(1):115-124.
3. Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399(10336):1695-1707.